Celldex Therapeutics Inc.
CLDX
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.78B
Close$
$0.04
99.9% downside
Current Fair Value
99.9% downsideOvervalued by 99.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.78 Billion |
|---|---|
| Enterprise Value | $2.73 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.9 |
| Beta | 0.9 |
| Outstanding Shares | 77,840,000 |
Return
| Return on Equity | -42.07% |
|---|---|
| Return on Assets | -38.42% |
| Return on Invested Capital | -20.58% |
Valuation & Multiples
| P/E Ratio | -9.57 |
|---|---|
| PEG | -32.03 |
| Price to Sales | - |
| Price to Book Ratio | 4.73 |
| Enterprise Value to Revenue | 24399.73 |
| Enterprise Value to EBIT | -18.41 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-1.06
Average shareholder expectationRevenue Estimate
$734,917
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-1.03
Average shareholder expectationRevenue Estimate
$725,750
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.6977▼ 22.85% |
|---|---|
| Total Calls | 129▼ 99.87% |
| Total Puts | 219▼ 99.89% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 24.83%▼ 84.74% |
|---|---|
| Total Invested | $614.70M▼ 73.42% |
| Investors Holding | 79▼ 155.00% |
ESG Score
No data
About Celldex Therapeutics Inc.
CEO: Anthony Marucci Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeu...